A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 25, 2023

Primary Completion Date

September 25, 2024

Study Completion Date

October 25, 2024

Conditions

Oral Squamous Cell Carcinoma

Interventions

DRUG

Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy

All Listed Sponsors

lead

Xuekui Liu

OTHER